Infection

Papers
(The H4-Index of Infection is 43. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-03-01 to 2024-03-01.)
ArticleCitations
First case of COVID-19 complicated with fulminant myocarditis: a case report and insights330
Risk factors for Covid-19 severity and fatality: a structured literature review316
Long COVID, a comprehensive systematic scoping review167
Clinical characteristics of 145 patients with corona virus disease 2019 (COVID-19) in Taizhou, Zhejiang, China164
COVID-19 outbreak: history, mechanism, transmission, structural studies and therapeutics148
COVID-19 in people living with human immunodeficiency virus: a case series of 33 patients140
Epidemiology of SARS-CoV-2140
Clinical characteristics of COVID-19 in children compared with adults in Shandong Province, China126
Efficacy of commercial mouth-rinses on SARS-CoV-2 viral load in saliva: randomized control trial in Singapore120
A highly specific and sensitive serological assay detects SARS-CoV-2 antibody levels in COVID-19 patients that correlate with neutralization105
Successful containment of COVID-19: the WHO-Report on the COVID-19 outbreak in China104
State-of-the-art review of secondary pulmonary infections in patients with COVID-19 pneumonia103
COVID-19 and mucormycosis superinfection: the perfect storm99
A challenging complication following SARS-CoV-2 infection: a case of pulmonary mucormycosis97
Waves and variants of SARS-CoV-2: understanding the causes and effect of the COVID-19 catastrophe93
Long COVID: current definition85
Higher viral loads in asymptomatic COVID-19 patients might be the invisible part of the iceberg81
Treatment options for K. pneumoniae, P. aeruginosa and A. baumannii co-resistant to carbapenems, aminoglycosides, polymyxins and tigecycline: an approach based on the mechanisms of resistance to carba80
Multidrug-resistant Acinetobacter baumannii infections in COVID-19 patients hospitalized in intensive care unit79
Clinical and virological features of first human monkeypox cases in Germany79
Studying the pathophysiology of coronavirus disease 2019: a protocol for the Berlin prospective COVID-19 patient cohort (Pa-COVID-19)75
Differences and similarities between SARS-CoV and SARS-CoV-2: spike receptor-binding domain recognition and host cell infection with support of cellular serine proteases74
Metagenomic next-generation sequencing in the diagnosis of severe pneumonias caused by Chlamydia psittaci73
C-reactive protein and procalcitonin for antimicrobial stewardship in COVID-1969
Perceived versus proven SARS-CoV-2-specific immune responses in health-care professionals64
Increasing influenza vaccination coverage in healthcare workers: a review on campaign strategies and their effect60
Bacterial coinfection in critically ill COVID-19 patients with severe pneumonia59
Pulmonary function in patients surviving to COVID-19 pneumonia58
Remdesivir in Coronavirus Disease 2019 (COVID-19) treatment: a review of evidence58
Recommendations for screening, monitoring, prevention, and prophylaxis of infections in adult and pediatric patients receiving CAR T-cell therapy: a position paper57
SARS-CoV-2 spike protein: pathogenesis, vaccines, and potential therapies57
Older age groups and country-specific case fatality rates of COVID-19 in Europe, USA and Canada55
Recurrence of COVID-19 after recovery: a case report from Italy52
Cardiac manifestations of COVID-19 in Shenzhen, China50
COVID-19 symptoms at hospital admission vary with age and sex: results from the ISARIC prospective multinational observational study50
First results of the “Lean European Open Survey on SARS-CoV-2-Infected Patients (LEOSS)”49
COVID-19: persistence of symptoms and lung alterations after 3–6 months from hospital discharge49
Contribution of anosmia and dysgeusia for diagnostic of COVID-19 in outpatients46
CD169/SIGLEC1 is expressed on circulating monocytes in COVID-19 and expression levels are associated with disease severity46
Strongyloides infection manifested during immunosuppressive therapy for SARS-CoV-2 pneumonia44
Waning antibody responses in COVID-19: what can we learn from the analysis of other coronaviruses?43
Comparing the clinical characteristics and outcomes of COVID-19-associate pulmonary aspergillosis (CAPA): a systematic review and meta-analysis43
SARS-CoV-2-directed antibodies persist for more than six months in a cohort with mild to moderate COVID-1943
0.071309089660645